Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
(4) - EconoTimes)
BOSTON, Dec. 29, 2017 -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant to two employees of inducement stock options exercisable for an aggregate of 37,000 shares of Albireo’s common stock. The stock options are exercisable at a price of $26.12 per share, the closing price of Albireo’s common stock on December 28, 2017, the grant date, and were granted as inducements material to each employee’s acceptance of employment with Albireo in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has a 10-year term and vests over a four-year period, subject to the employee’s continued service with Albireo through the applicable vesting dates. The vesting schedule for each stock option is 25 percent on the one-year anniversary of the employee’s start date with Albireo and 75 percent in equal installments on the last day of the 12 consecutive quarters beginning with December 31, 2018. The stock options are subject to the terms and conditions of Albireo’s 2017 Inducement Equity Incentive Plan.
About Albireo
Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo's clinical pipeline includes a Phase 3 product candidate, a Phase 2 product candidate and a product candidate for which an application for regulatory approval has been submitted in Japan. Albireo was spun out from AstraZeneca in 2008.
Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
Investor Contact:
Hans Vitzthum
LifeSci Advisors, LLC.
212-915-2568
Media Contact:
Heather Anderson
6 Degrees
980-938-0260
[email protected]
Source: Albireo Pharma, Inc.
